ARVEE - Arvee Laborat.
📢 Recent Corporate Announcements
Arvee Laboratories has responded to a surveillance query from the National Stock Exchange regarding recent significant fluctuations in its share price. The company officially stated that it is in full compliance with all SEBI Listing Obligations and Disclosure Requirements. Management clarified that there are no undisclosed material events or information that would necessitate a public announcement. Consequently, the company attributed the price movement solely to market-driven factors and shareholder transactions.
- NSE issued a clarification request on December 19, 2025, regarding unusual price movement
- Company confirmed adherence to SEBI (LODR) Regulations, 2015, in its response dated December 24, 2025
- Management explicitly stated there are no material events requiring new disclosures to the exchange
- The price movement was categorized as being driven entirely by market participants and shareholders
Arvee Laboratories reported a strong sequential and year-on-year recovery in Q3 FY26, with revenue reaching ₹977.95 Lakhs compared to ₹345.05 Lakhs in the previous quarter. Net profit for the quarter stood at ₹182.69 Lakhs, a significant jump from ₹15.48 Lakhs in Q3 FY25, though this was aided by a deferred tax credit of ₹66.09 Lakhs. Despite the strong quarter, the nine-month revenue of ₹2,071 Lakhs still lags significantly behind the ₹3,203.72 Lakhs recorded in the same period last year. The non-textile segment continues to be the primary revenue driver, contributing approximately 89% of the total quarterly income.
- Revenue from operations grew 9.8% YoY to ₹977.95 Lakhs in Q3 FY26.
- Net Profit for the quarter increased to ₹182.69 Lakhs from ₹15.48 Lakhs in the previous year's corresponding quarter.
- Quarterly Earnings Per Share (EPS) rose to ₹1.66 from ₹0.14 YoY.
- Non-textile segment revenue dominated at ₹881.88 Lakhs, while the textile segment contributed ₹109.71 Lakhs.
- Total expenses for the nine-month period decreased to ₹1,966.80 Lakhs from ₹2,970.93 Lakhs YoY.
Arvee Laboratories (India) Limited has issued a corrigendum to its previous notice regarding the Board Meeting scheduled for February 13, 2026. The update clarifies a typographical error concerning the trading window closure for insiders. The trading window has been officially closed since January 1, 2026, and will remain so until 48 hours after the declaration of financial results for the quarter ended December 31, 2025. This is a routine regulatory filing to ensure compliance with insider trading norms.
- Board Meeting scheduled for February 13, 2026, to approve Q3 FY26 financial results
- Trading window for insiders closed effective from January 1, 2026
- Trading window to remain closed until 2 working days after the financial result declaration
- Corrigendum corrects typographical errors in the previous communication dated February 5, 2026
Arvee Laboratories (India) Limited has officially notified the exchange regarding the closure of its trading window for all designated persons. This closure is effective from January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the company's financial results for this period are declared. This is a standard regulatory procedure to prevent insider trading ahead of earnings announcements.
- Trading window closure commences on January 1, 2026
- Closure pertains to the financial period ending December 31, 2025
- Restriction applies to Promoters, Directors, KMPs, and Designated Persons
- Window will reopen 48 hours after the declaration of quarterly financial results
Arvee Laboratories (India) Limited has responded to a surveillance query from the National Stock Exchange regarding recent significant movements in its share price. In its clarification dated December 24, 2025, the company stated that it is in full compliance with all SEBI disclosure regulations. The company confirmed that there are no undisclosed material events or information that would explain the price volatility. Management noted that the price movement is determined by market participants and shareholders rather than internal corporate actions.
- Response to NSE surveillance letter Ref. No. NSE/CM/Surveillance/16199 dated December 19, 2025
- Company confirms full compliance with SEBI (LODR) Regulations, 2015
- No material information or events remain undisclosed to the exchanges
- Stock price movement attributed solely to market forces and shareholder transactions
Financial Performance
Revenue Growth by Segment
Total Revenue from Operations grew 26.83% YoY to INR 38.49 Cr in FY25. Domestic manufacturing sales grew 34.1% to INR 31.45 Cr, while export manufacturing sales declined 20.9% to INR 5.30 Cr. Domestic trading contributed INR 0.35 Cr and export trading INR 0.34 Cr.
Geographic Revenue Split
Domestic sales (India) account for 81.7% of revenue (INR 31.45 Cr), while Export sales account for 13.8% (INR 5.30 Cr). Other operating income contributes the remaining 4.5%.
Profitability Margins
Net Profit Margin improved from 3.46% in FY24 to 5.58% in FY25. Net Profit grew 104.15% YoY to INR 2.15 Cr, driven by higher revenue and a 23.3% reduction in depreciation expenses (from INR 1.50 Cr to INR 1.15 Cr).
EBITDA Margin
EBITDA Margin was 11.1% in FY25 (INR 4.27 Cr) compared to 11.8% in FY24 (INR 3.58 Cr). Core profitability slightly contracted despite the net profit surge due to higher raw material consumption costs.
Credit Rating & Borrowing
Non-current borrowings stood at INR 1.03 Cr as of March 31, 2025. Finance costs for FY25 were INR 0.25 Cr, representing a marginal 0.5% decrease YoY. Specific credit ratings and interest rate percentages were not disclosed.
Operational Drivers
Raw Materials
Chemical raw materials (Specific names like benzene or specialty feedstocks not disclosed) represent 49% of total revenue, totaling INR 18.87 Cr in FY25.
Raw Material Costs
Raw material costs were INR 18.87 Cr in FY25, up from INR 15.12 Cr in FY24 (a 24.8% increase), tracking closely with revenue growth. Procurement is managed to mitigate price volatility in the chemical market.
Strategic Growth
Growth Strategy
The company aims to achieve growth by increasing profitability through operational efficiencies and focusing on its manufacturing segment, which saw 34.1% domestic growth. Management is taking steps to mitigate risks from currency fluctuations and market price volatility to stabilize margins.
Products & Services
Chemical products manufactured and traded for industrial use (Specific product names not disclosed).
Brand Portfolio
Arvee Laboratories.
External Factors
Industry Trends
The chemical industry is characterized by intense competition and regulatory changes. Arvee is positioning itself by maintaining cost records and following relevant accounting standards, though it faces pressure from market-linked pricing.
Competitive Landscape
Faces 'intense competition' which management notes may limit growth prospects and pricing ability.
Competitive Moat
The company lacks a durable moat; it operates in a highly competitive market where products are subject to prevailing market prices, and it faces significant promoter dependency.
Macro Economic Sensitivity
The business is sensitive to global economic and social conditions which can increase costs and negatively affect stock prices. H1 FY26 results show a 92.82% collapse in PBT, indicating high sensitivity to macro-driven revenue drops.
Geopolitical Risks
Global political conditions are cited as risks that could harm the ability to do business and increase operational costs.
Regulatory & Governance
Industry Regulations
Subject to the Companies Act 2013 for cost record maintenance. The company received a secretarial qualification for failing to file the Cost Report on time for FY25.
Taxation Policy Impact
Effective tax rate for FY25 was approximately 25.2% (INR 0.72 Cr tax on INR 2.87 Cr PBT).
Legal Contingencies
The company reports nil pending litigations that would impact its financial position as of March 31, 2025. No material foreseeable losses on long-term contracts were reported.
Risk Analysis
Key Uncertainties
Key risks include currency fluctuation, regulatory changes, and manufacturing supply disruptions. The 52.7% YoY revenue drop in H1 FY26 represents a critical uncertainty regarding demand stability.
Geographic Concentration Risk
High geographic concentration with 81.7% of revenue derived from the Indian domestic market.
Technology Obsolescence Risk
Information Technology is identified as a major risk area, requiring ongoing management to prevent operational disruptions.
Credit & Counterparty Risk
Trade receivables turnover improved 60.6% to 5.30 in FY25, indicating improved credit management and faster collections from customers.